secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-262519
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon Q3 net loss $90.9M, Phase 3 FOS study fully enrolled, new CFO appointed
-----------------------------------------------------------------------------

- Net loss $90.9M (vs $62.8M Q3 2024) on higher R&D spend; R&D expenses $77.1M (vs $57.0M).
- Phase 3 X-TOLE2 FOS study completed enrollment (380 patients); topline data expected early 2026.
- Phase 3 MDD (X-NOVA2/3) and BPD (X-CEED) studies continue recruiting; Phase 1 Nav1.7 and Kv7 studies underway.
- Tucker Kelly appointed CFO to lead finance strategy ahead of azetukalner launch.
- Cash $555.3M as of Sept 30, 2025; runway into 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312525262519/0001193125-25-262519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312525262519/xene-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-262519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer